Regeneron's covid-19 cocktail of casirivimab and imdevimab gets expanded use authorization from the US Food and Drug Admin on Friday. The authorization allows for post exposure propholaxis for those exposed to infected person, people in institutional settings at higher exposure risk and immunocompromised patients. People will also be allowed to receive it monthly for ongoing exposure.

Regeneron's covid-19 cocktail of casirivimab and imdevimab gets expanded use authorization from the US Food and Drug Admin.  The authorization allows for post exposure propholaxis for those exposed to infected person, people in institutional settings at higher exposure risk and immunocompromised patients.  People will also be allowed to receive it monthly for ongoing exposure.